PepGen was spun out from the University of Oxford (OU) and the Medical Research Council (MRC). The company's technology platform is based on intellectual property developed through a collaboration between Professor Matthew Wood (OU) and Dr Michael Gait (MRC). Dr Caroline Godfrey and Dr Giles Campion are the company's co-founders, with Dr Godfrey serving as the CEO.
The company received an initial £2.5M seed funding from Oxford Sciences Innovation (OSI). It will focus on pre-clinical validation of the peptide delivery platform before moving towards commercialization of the technology for various indications. The company's founding Board of Directors includes Dr Wood, Dr Godfrey, and Dr Andrew Mclean (OSI).
PepGen has a 44 m2 chemistry lab, a 21 m2 biology lab, and a 15 m2 office in the BioEscalator, with the option to move into larger premises as the company expands. The company is setting up these spaces to build internal synthetic and analytical capabilities, with critical equipment including peptide synthesizers, Maldi-ToF, quantitative HPLC, and RT-PCR/qPCR devices.